Clinical Trial Update: A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib study of the selective PKC-β inhibitor MS-553 in patients with refractory or relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• MS-553 (MS-553)

Snippet

Sponsor: MingSight Pharmaceuticals, Inc | Conditions: CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING